Looking into well-known oncogenes and TSGs, we identified gains of EGFR in “de novo glioma pathway” (2 in LGG and 3 in HGG), as well as MDM2 (1 in LGG and 3 in HGG) and PTEN (1 in HGG), and losses of CDKN2A (2 in HGG). The gene discussed is MDM2; the disease is central nervous system cancer.